Skip to content
Peptides Networkby Compounded Health
Menu

Profile

PT-141 (Bremelanotide)

The peptide in Vyleesi®: what FDA approved it for, which trial outcomes improved, and which did not

4 min read Evidence checked October 18, 2026 Key takeaways 11 sources

In this article

Key takeaways

Bremelanotide (PT-141) is the peptide in Vyleesi® (Cosette Pharmaceuticals), FDA-approved only for acquired, generalized HSDD in premenopausal women. In two 24-week trials it modestly improved desire and distress scores; the number of satisfying sexual events did not differ from placebo.

Evidence available
Randomized trials in people
Confidence
Moderate Two large placebo-controlled phase 3 trials with prespecified endpoints agree, but the improvements were small and the event-count endpoint was null.
Main limitation
The trials lasted 24 weeks, enrolled mostly white women at US sites and were funded by the companies developing the drug.
Evidence checked See all 11 sources

At a glance

Diagram of the amino acid sequence of bremelanotide (PT-141): 7 residues drawn as a chain of lettered beads with six residues in a ring closed by a lactam bridge, with norleucine and D-phenylalanine highlighted, and an acetyl cap and C-terminal acid, under its name, formula and molecular weight.
Bremelanotide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Drawn by Peptides Network from PubChem CID 9941379.
Category
Sexual Health / Melanocortin
Mechanism
Melanocortin receptor agonist (MC4R and other subtypes). The FDA label states that the mechanism by which it improves sexual desire in women is unknown.
Classification
Cyclic heptapeptide melanocortin receptor agonist (synthetic)
Molecular weight
1025.19 Da
Half-life
2.7 hours
Brand name
Vyleesi® (Cosette Pharmaceuticals)
Molecular formula
C50H68N14O10
Amino acids
7
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

U.S. regulatory status

  • Bremelanotide injectionVyleesi® (Cosette Pharmaceuticals)

    FDA-approved for this use

    Premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance; not indicated for postmenopausal women, for men, or to enhance sexual performance

    Source 5, verified

  • Flibanserin tabletsAddyi® (Sprout Pharmaceuticals)

    FDA-approved for this use

    Women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance

    Source 8, verified

Bremelanotide, also called PT-141 11, is the peptide in Vyleesi® (Cosette Pharmaceuticals), an injection FDA approved in June 2019 6. Its only approved use is in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or difficulty between partners and is not due to another medical or psychiatric condition, problems in the relationship, or the effects of a medicine or drug 5. In the two phase 3 trials behind the approval, women on bremelanotide reported small improvements in desire and less distress about low desire than women on placebo, but the number of satisfying sexual events, the trials’ key secondary measure, did not differ between the groups 1,5.

What Vyleesi® is approved for, and what it is not

“Acquired” means the low desire developed in someone who previously had no problem with desire; “generalized” means it occurs regardless of the type of stimulation, situation or partner. The label states that Vyleesi® is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance 5.

Bremelanotide was the second medicine FDA approved for HSDD, not the first 4. Addyi® (flibanserin, Sprout Pharmaceuticals), a tablet, was approved in August 2015 7, and its current label covers women younger than 65 with acquired, generalized HSDD 8. Flibanserin acts on serotonin receptors, not on sex hormones 3, so bremelanotide was not the first non-hormonal option either. The earlier version of this page called it the first and only FDA-approved non-hormonal treatment for HSDD; that was wrong.

What the RECONNECT trials found

The two trials, RECONNECT studies 301 and 302 (NCT02333071 and NCT02338960), randomized 1,267 premenopausal women with HSDD to bremelanotide or placebo for 24 weeks 1,9,10. Most participants were white (85.6 percent) and enrolled at US sites (96.6 percent), and their mean age was 39 1. Palatin Technologies sponsored the trials 9,10, and Palatin and AMAG Pharmaceuticals funded them 1.

The two main measures were a desire score from the Female Sexual Function Index, which runs from 1.2 to 6, and a question on how often a woman felt bothered by low desire, scored from 0 to 4 5. Compared with placebo, the desire score rose by 0.30 and 0.42 points more in the two studies, and the distress score fell by 0.37 and 0.29 points more; all four differences were statistically significant 1. A 2020 review of the trials judged that the clinical benefit may be modest 4.

The key secondary measure was the change in the number of satisfying sexual events. It did not differ between the groups in either study: the average change was 0.0 events with bremelanotide in both studies, against −0.1 and 0.0 with placebo 1,5. Because this measure failed, the trials’ remaining secondary measures counted only as supportive and exploratory under the statistical analysis plan 1. The earlier version of this page said the trials found a statistically significant increase in satisfying sexual events; they did not.

After the 24 weeks, 684 women entered a 52-week open-label extension in which everyone received bremelanotide, and 272 completed it 2. Desire and distress scores stayed improved during the extension, but there was no placebo group and the analyses were descriptive 2.

How it works

Bremelanotide activates several melanocortin receptors; at the doses used, binding to MC1R and MC4R matters most 5. MC4R is found in many areas of the brain, and animal studies suggest bremelanotide acts on MC4R in the medial preoptic area of the hypothalamus, increasing the release of dopamine there 3. The label states that the mechanism by which Vyleesi® improves HSDD in women is unknown 5. MC1R is found on the skin’s pigment cells, and binding there increases pigmentation 5.

Side effects and warnings

In the placebo-controlled trials, nausea was reported by 40.0 percent of women on Vyleesi® and 1.3 percent on placebo, flushing by 20.3 and 0.3 percent, injection-site reactions by 13.2 and 8.4 percent, and headache by 11.3 and 1.9 percent 5. Side effects led 18 percent of women on Vyleesi® to stop, against 2 percent on placebo; nausea was the most common reason (8 percent) 5.

Blood pressure rises briefly after each dose, by up to 6 mmHg systolic and 3 mmHg diastolic at its peak, with a small fall in heart rate; both usually return to baseline within 12 hours 5. Vyleesi® is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and the label does not recommend it for people at high risk of cardiovascular disease 5.

Darkening of patches of skin, including on the face, gums and breasts, was reported by 1 percent of women in the phase 3 trials. It was more common with more frequent use and in people with darker skin, and in some it was not confirmed to have resolved 5. Bremelanotide can also lower how much oral naltrexone the body absorbs, and the label says to avoid using it with oral naltrexone products for alcohol or opioid dependence 5. The prescribing information is the complete list.

Topics

  • bremelanotide
  • PT-141
  • HSDD
  • melanocortin
  • FDA-approved

Sources

11 sources. Numbers in the text link to the entry they cite.

  1. 1.
    Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019.

    Randomized controlled trial PMID 31599840 DOI 10.1097/AOG.0000000000003500Checked October 18, 2026

    Cited for: RECONNECT studies 301 and 302; 1,267 randomized, 24 weeks; 85.6% white, 96.6% US sites, mean age 39; desire +0.30 and +0.42, distress -0.37 and -0.29 vs placebo (all significant); satisfying sexual events not significant (0.0 vs -0.1, P=.764; 0.0 vs 0.0, P=.702), remaining secondary endpoints supportive and exploratory; funded by Palatin and AMAG

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)

  2. 2.
    Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

    Simon JA, Kingsberg SA, Portman D, et al. Obstet Gynecol. 2019.

    Other source PMID 31599847 DOI 10.1097/AOG.0000000000003514Checked October 18, 2026

    Cited for: 52-week open-label extension; 684 of 856 eligible enrolled, 272 completed; analyses descriptive; sustained desire and distress improvements

    Back to text (a)Back to text (b)

  3. 3.
    The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women

    Pfaus JG, Sadiq A, Spana C, Clayton AH. CNS Spectr. 2022.

    Review PMID 33455598 DOI 10.1017/S109285292100002XChecked October 18, 2026

    Cited for: Flibanserin a serotonin mixed agonist and antagonist; MC4R most relevant; animal studies suggest MC4R in the medial preoptic area and dopamine release

    Back to text (a)Back to text (b)

  4. 4.
    Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

    Mayer D, Lynch SE. Ann Pharmacother. 2020.

    Systematic review PMID 31893927 DOI 10.1177/1060028019899152Checked October 18, 2026

    Cited for: Bremelanotide is the second FDA-approved medication for HSDD; the clinical benefit may only be modest

    Back to text (a)Back to text (b)

  5. 5.
    VYLEESI (bremelanotide) injection, for subcutaneous use: prescribing information (effective 2025-11-13)

    Cosette Pharmaceuticals. DailyMed. 2025.

    Product labeldailymed.nlm.nih.govChecked October 18, 2026

    Cited for: Indication and limitations of use (1); contraindications (4); transient BP increase up to 6/3 mmHg, usually resolving within 12 hours (5.1); focal hyperpigmentation 1%, higher with darker skin and daily dosing, not resolved in some (5.2); naltrexone (7.2); adverse reactions Table 1 and discontinuation 18% vs 2% (6.1); mechanism unknown, MC1R and MC4R (12.1); FSFI and FSDS-DAO scales and SSE Table 4 (14); Cosette Pharmaceuticals

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)Back to text (h)Back to text (i)Back to text (j)Back to text (k)Back to text (l)Back to text (m)Back to text (n)

  6. 6.
    Drugs@FDA: NDA 210557, VYLEESI (bremelanotide), Cosette

    U.S. Food and Drug Administration. Drugs@FDA. 2019.

    Regulatory documentaccessdata.fda.govChecked October 18, 2026

    Cited for: Original approval 2019-06-21 (Type 1, new molecular entity); current applicant Cosette

    Back to text

  7. 7.
    Drugs@FDA: NDA 022526, ADDYI (flibanserin), Sprout Pharms

    U.S. Food and Drug Administration. Drugs@FDA. 2015.

    Regulatory documentaccessdata.fda.govChecked October 18, 2026

    Cited for: Original approval 2015-08-18 (Type 1, new molecular entity)

    Back to text

  8. 8.
    ADDYI (flibanserin) tablets, for oral use: prescribing information (effective 2025-12-22)

    Sprout Pharmaceuticals. DailyMed. 2025.

    Product labeldailymed.nlm.nih.govChecked October 18, 2026

    Cited for: Indication: women less than 65 years of age with acquired, generalized HSDD (1); Sprout Pharmaceuticals

    Back to text

  9. 9.
    Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (study 301)

    Palatin Technologies. ClinicalTrials.gov. 2015.

    Trial registrationNCT02333071Checked October 18, 2026

    Cited for: RECONNECT study 301 registration; sponsor Palatin Technologies; completed

    Back to text (a)Back to text (b)

  10. 10.
    Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (study 302)

    Palatin Technologies. ClinicalTrials.gov. 2015.

    Trial registrationNCT02338960Checked October 18, 2026

    Cited for: RECONNECT study 302 registration; sponsor Palatin Technologies; completed

    Back to text (a)Back to text (b)

  11. 11.
    bremelanotide (MeSH Supplementary Concept C476721)

    National Library of Medicine. MeSH.

    Other sourcencbi.nlm.nih.govChecked October 18, 2026

    Cited for: Entry terms bremelanotide, PT-141, Vyleesi

    Back to text

Next read

Follow Compounded Health InstagramFacebook

Back to Peptides Network Back to top